Synthetic Biology's Defense Dollars: Signals and Perceptions
By Dr. Filippa Lentzos,
PLOS Blogs
| 12. 24. 2015
Untitled Document
Synthetic biology is swimming in defense dollars. The most recent figures available on US trends in synthetic biology research funding indicate that two thirds of the $200 million invested in 2014 came from the Department of Defense or its research agency DARPA. While many scientists see military money as just another source of funding on par with NIH or NSF funding—after all, the majority of the funds are for basic science without security classification and publication restrictions—there are good reasons not to brush it off. One of these is the perception of the field to outsiders.
From an international security perspective, the extensive influx of military funding can be perceived as threatening to analysts in other countries following these developments. The US Department of Defense declared just over $655 million on national biodefence research in 2014. Synthetic biology research appears, therefore, to make up about a fifth of the biodefence budget. DARPA aims not only to develop radically new, game-changing technologies for national security in order to maintain US technological supremacy, it also aims to create technological surprise...
Related Articles
By Holly Baxter, The Independent | 08.19.2025
In rural Pennsylvania, I’m hiking through the forest with Simone and Malcom Collins and discussing the executive order they wrote for Donald Trump. Just outside their house — beyond the chicken coop, where they gather their eggs for homemade cakes...
By Jacob Bogage, The Washington Post | 09.03.2025
The conservative group behind the Project 2025 governing playbook for President Donald Trump’s second term is set to propose sweeping revisions to U.S. economic policy meant to encourage married heterosexual couples to have more children.
The Heritage Foundation, a right-wing...
By Dennis Sponer, BioSpace | 09.03.2025
Imagine telling a child with sickle cell disease that a cure exists—but it’s too expensive for their insurer to cover. That’s not a hypothetical. It’s the reality of gene therapy today: a revolutionary medical breakthrough caught in the bottleneck of...
By Tia Ghose, Live Science | 09.16.2025
Twenty-six years ago today, on Sept. 17, a teenager who had received an experimental gene therapy died. His death led to needed changes in the clinical trial process while also spurring skepticism that would ultimately stall the field of gene...